September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers
April 9th 2018Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Watch
Rova-T Delivers Disappointing Results in Phase II SCLC Trial
April 5th 2018In preliminary findings from the single-arm, phase II TRINITY trial investigating Rovalpituzumab Tesirine (Rova-T) in the third-line setting for patients with relapsed/refractory small cell lung cancer (SCLC) demonstrating high DLL3 expression, the DLL3-targeted antobody-drug conjugate delivered disappointing results.
Read More
Priority Review Granted by FDA to Dacomitinib for Frontline Treatment in NSCLC
April 5th 2018According to Pfizer, manufacturer of a pan-human EGFR tyrosine kinase inhibitor (TKI), a priority review has been granted by the FDA for their TKI inhibitor, dacomitinib, in the frontline setting for patients with <em>EGFR</em>-positive locally advanced or metastatic non–small cell lung cancer.
Read More
Kris on the Success of Durvalumab as a Major Advancement in NSCLC
April 3rd 2018In an interview with <em>Targeted Oncology</em>, Kris, a medical oncologist and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, discussed how the approval of durvalumab has changed the treatment landscape of NSCLC.
Read More
Fabrice Barlesi Selected to Receive the Heine H. Hansen Award by ESMO and IASLC
March 30th 2018The European Society for Medical Oncology in conjunction with the International Association for the Study of Lung Cancer has selected Fabrice Barlesi, MD, PhD, to receive the 2018 Heine H. Hansen Award. Barlesi will be presented with the award at the 2018 European Lung Cancer Congress, which will be held April 11-14 in Geneva, Switzerland.
Read More
New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene Fusion
March 27th 2018The new drug application for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion has been completed.
Read More
Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC
March 27th 2018The treatment landscape of non-small cell lung cancer has been identifying the importance of immunotherapy already, but combination therapies will soon play a large role in treatment of these patients as well, according to Chad Pecot, MD.
Read More
Study Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC
March 26th 2018According to findings from the phase III IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.
Read More